CY2020023I2 - Αναστολεiς βητα-λακταμασων - Google Patents

Αναστολεiς βητα-λακταμασων

Info

Publication number
CY2020023I2
CY2020023I2 CY2020023C CY2020023C CY2020023I2 CY 2020023 I2 CY2020023 I2 CY 2020023I2 CY 2020023 C CY2020023 C CY 2020023C CY 2020023 C CY2020023 C CY 2020023C CY 2020023 I2 CY2020023 I2 CY 2020023I2
Authority
CY
Cyprus
Prior art keywords
lactamas
inhibitors
beta
lactamas inhibitors
Prior art date
Application number
CY2020023C
Other languages
English (en)
Other versions
CY2020023I1 (el
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY2020023I2 publication Critical patent/CY2020023I2/el
Publication of CY2020023I1 publication Critical patent/CY2020023I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CY2020023C 2008-01-18 2020-07-15 Αναστολεiς βητα-λακταμασων CY2020023I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1153308P 2008-01-18 2008-01-18
EP09701487.2A EP2231667B1 (en) 2008-01-18 2009-01-15 Beta-lactamase inhibitors

Publications (2)

Publication Number Publication Date
CY2020023I2 true CY2020023I2 (el) 2020-11-25
CY2020023I1 CY2020023I1 (el) 2020-11-25

Family

ID=40642204

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20131101079T CY1114900T1 (el) 2008-01-18 2013-12-03 Αναστολεις βητα-λακταμασων
CY20151100288T CY1116243T1 (el) 2008-01-18 2015-03-23 Αναστολεiς βητα-λακταμασων
CY2020023C CY2020023I1 (el) 2008-01-18 2020-07-15 Αναστολεiς βητα-λακταμασων
CY2020025C CY2020025I2 (el) 2008-01-18 2020-07-15 Αναστολεις βητα-λακταμασων
CY2020024C CY2020024I2 (el) 2008-01-18 2020-07-15 Αναστολεiς βητα-λακταμασων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20131101079T CY1114900T1 (el) 2008-01-18 2013-12-03 Αναστολεις βητα-λακταμασων
CY20151100288T CY1116243T1 (el) 2008-01-18 2015-03-23 Αναστολεiς βητα-λακταμασων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2020025C CY2020025I2 (el) 2008-01-18 2020-07-15 Αναστολεις βητα-λακταμασων
CY2020024C CY2020024I2 (el) 2008-01-18 2020-07-15 Αναστολεiς βητα-λακταμασων

Country Status (39)

Country Link
US (2) US8487093B2 (el)
EP (2) EP2666774B1 (el)
JP (3) JP5038509B2 (el)
KR (2) KR101800610B1 (el)
CN (2) CN102827067B (el)
AU (1) AU2009206119C1 (el)
BR (1) BRPI0906871B1 (el)
CA (1) CA2712783C (el)
CO (1) CO6331438A2 (el)
CR (1) CR11626A (el)
CY (5) CY1114900T1 (el)
DK (2) DK2231667T3 (el)
DO (1) DOP2010000218A (el)
EC (2) ECSP10010345A (el)
ES (2) ES2533826T3 (el)
FR (3) FR20C1030I2 (el)
HK (2) HK1143809A1 (el)
HN (1) HN2010001395A (el)
HR (2) HRP20131123T1 (el)
HU (2) HUS000513I2 (el)
IL (1) IL206395A (el)
LT (3) LTC2231667I2 (el)
LU (1) LUC00165I2 (el)
MA (1) MA32025B1 (el)
ME (1) ME02089B (el)
MX (1) MX2010007823A (el)
MY (1) MY162532A (el)
NI (1) NI201000115A (el)
NL (2) NL301051I2 (el)
NO (1) NO2020024I1 (el)
NZ (1) NZ586861A (el)
PL (2) PL2231667T3 (el)
PT (2) PT2666774E (el)
RS (2) RS53862B1 (el)
RU (1) RU2445314C9 (el)
SI (2) SI2231667T1 (el)
UA (1) UA101966C2 (el)
WO (1) WO2009091856A2 (el)
ZA (1) ZA201005333B (el)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2712783C (en) * 2008-01-18 2013-03-19 Timothy A. Blizzard Beta-lactamase inhibitors
ES2691468T3 (es) 2010-08-10 2018-11-27 Rempex Pharmaceuticals, Inc. Derivados de éster del ácido borónico cíclicos y usos terapéuticos de los mismos
DK2657234T3 (da) * 2010-12-22 2017-02-20 Meiji Seika Pharma Co Ltd Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
EP2721005B1 (en) * 2011-06-17 2015-11-25 AstraZeneca AB Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
CN103619843B (zh) 2011-08-27 2017-01-11 沃克哈特有限公司 1，6‑二氮杂双环[3，2，1]辛‑7‑酮衍生物及其在治疗细菌感染中的用途
AU2012303693B2 (en) 2011-08-30 2014-07-03 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
MX2014008278A (es) 2012-01-06 2014-11-10 Univ South Florida Composiciones, metodos de uso y metodos de tratamiento.
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
EP2831069B1 (en) * 2012-03-30 2017-07-12 Merck Sharp & Dohme Corp. Isoxazole beta-lactamase inhibitors
US8969570B2 (en) * 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2847327B1 (en) 2012-05-08 2018-12-26 Codexis, Inc. Biocatalysts and methods for hydroxylation of chemical compounds
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
KR101946107B1 (ko) * 2012-08-25 2019-02-08 욱크하르트 리미티드 １,６-디아자비시클로〔３,２,１〕옥탄-７-온 유도체 및 세균 감염의 치료에서의 이의 용도
JPWO2014069351A1 (ja) * 2012-11-01 2016-09-08 株式会社カネカ 光学活性二環式ウレア化合物の製造方法
RU2654692C2 (ru) * 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамаз
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2016509594A (ja) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP6324409B2 (ja) 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014110442A1 (en) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
AU2013380573B2 (en) * 2013-03-08 2016-07-07 Wockhardt Limited A process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
KR101774132B1 (ko) 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
BR112015021186A2 (pt) 2013-03-08 2017-07-18 Wockhardt Ltd processo para a preparação de (2s,5r)-7-oxo-6-sulfóxi-2-[((3r)-pirrolidina-3-carbonil)-hidrazino carbonil]-1,6-diaza-biciclo[3.2.1]octano
BR112015021393A2 (pt) * 2013-03-08 2017-07-18 Wockhardt Ltd processo para a preparação de (2s,5r)-7-oxo-6-sulfoóxi-2-[(((3r)-piperidina-3-carbonil)-hidrazina carbonil]-1,6-diaza-biciclo[3.2.1]- octano
US9556174B2 (en) 2013-03-08 2017-01-31 Wockhardt Limited (2S, 5R)-sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6427173B2 (ja) * 2013-06-10 2018-11-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ｔｅｒｔ−ブチル ４−（（１Ｒ，２Ｓ，５Ｒ）−６−（ベンジルオキシ）−７−オキソ−１，６−ジアザビシクロ［３．２．１］オクタン−２−カルボキサミド）ピペリジン−１−カルボキシレートの調製
JP6453222B2 (ja) 2013-09-24 2019-01-16 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の製造法とその中間体
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
NZ757220A (en) * 2013-10-08 2021-12-24 Meiji Seika Pharma Co Ltd Crystalline forms of diazabicyclooctane derivative and production process thereof
EP3074397B1 (en) * 2013-11-26 2019-02-13 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
ES2719136T3 (es) 2014-03-24 2019-07-08 Novartis Ag Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
IN2014MU01195A (el) * 2014-03-29 2015-10-02 Wockhardt Ltd
IN2014MU01196A (el) * 2014-03-29 2015-10-02 Wockhardt Ltd
DK3140310T3 (da) 2014-05-05 2019-10-21 Rempex Pharmaceuticals Inc Syntese af boronatsalte og brug deraf
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3145936B1 (en) 2014-05-19 2020-09-30 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3164406A4 (en) 2014-07-01 2018-04-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN107108624B (zh) * 2014-11-17 2020-01-07 恩塔西斯治疗有限公司 用于治疗耐药性细菌感染的组合疗法
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3227306B1 (en) 2014-12-02 2020-07-15 Merck Sharp & Dohme Corp. Process for the preparation of tert-butyl 4-((2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof
MX2017007191A (es) 2014-12-05 2017-08-28 Meiji Seika Pharma Co Ltd Procedimiento de produccion de cristales de derivado de diazabiciclooctano y preparacion liofilizada estable.
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2715058C2 (ru) * 2015-03-31 2020-02-25 Мутабилис Гетероциклические соединения и их применение для предупреждения или лечения бактериальных инфекций
CN107580595B (zh) * 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
JP2018515481A (ja) * 2015-09-16 2018-06-14 シュアンチュー ファーマ カンパニー，リミティド β−ラクタマーゼ阻害剤とその利用
CA3000087A1 (en) 2015-10-02 2017-04-06 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3386982A1 (en) * 2015-12-11 2018-10-17 The Wockhardt Limited 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections
EP3411359B1 (en) 2016-02-04 2021-10-13 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
TW201736370A (zh) * 2016-03-31 2017-10-16 Xuanzhu Pharma Co Ltd 一種抗菌組合物及其用途
CN109715817B (zh) 2016-06-09 2022-12-09 科德克希思公司 用于化合物的羟基化的生物催化剂和方法
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
LT3512851T (lt) 2016-09-16 2022-10-25 Entasis Therapeutics Limited Beta-laktamazės inhibitorių junginiai
WO2018053057A2 (en) * 2016-09-19 2018-03-22 Merck Sharp & Dohme Corp. Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN108078982B (zh) * 2016-11-21 2020-02-07 天津大学 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
EP3592362A4 (en) 2017-03-06 2020-09-02 Venatorx Pharmaceuticals, Inc. SOLID FORMS AND COMBINATION COMPOSITIONS WITH A BETA LACTAMASE INHIBITOR AND USES THEREOF
CN108619141B (zh) * 2017-03-16 2021-09-10 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
ES2907858T3 (es) 2017-05-08 2022-04-26 Entasis Therapeutics Inc Compuestos y métodos para el tratamiento de infecciones bacterianas
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN110959008A (zh) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
JP2020528412A (ja) 2017-07-21 2020-09-24 アンタビオ エスアーエス 化学的化合物
CN109568323B (zh) * 2017-09-29 2022-09-30 吉林四环制药有限公司 抗菌组合物及其用途
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその合成
US11180501B2 (en) 2017-12-01 2021-11-23 Qilu Pharmaceutical Co., Ltd. Crystal form of β-lactamase inhibitor and preparation method therefor
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
EP3744722A4 (en) * 2018-01-25 2021-11-03 Suzhou Sinovent Pharmaceuticals Co., Ltd. Ss-LACTAMASE INHIBITOR AND ITS USE
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
WO2020030761A1 (en) * 2018-08-09 2020-02-13 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3670512A1 (en) * 2018-12-18 2020-06-24 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
CA3113606A1 (en) * 2018-09-21 2020-03-26 Api Corporation Method for producing amino acid derivatives
US11180500B2 (en) 2018-10-01 2021-11-23 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
MX2021011026A (es) 2019-03-12 2021-10-13 Arixa Pharmaceuticals Inc Forma cristalina de un derivado de avibactam.
EP3959205A4 (en) * 2019-04-26 2023-05-17 Merck Sharp & Dohme LLC METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE OF (2S,5R)-7-OXO-N-PIPERIDIN-4-YL-6-(SULFOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023220324A1 (en) * 2022-05-11 2023-11-16 The Regents Of The University Of Colorado A Body Corporate Antibiotic composition and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071843A (en) 1978-07-24 1991-12-10 Merck & Co., Inc. Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4880793A (en) 1978-07-24 1989-11-14 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4616038A (en) 1978-07-24 1986-10-07 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4539208A (en) 1980-09-17 1985-09-03 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
DK0508234T3 (da) 1991-04-11 1996-10-28 Hoffmann La Roche Beta-lactamer
PL179435B1 (pl) 1993-12-29 2000-09-29 Pfizer Diazabicykliczni antagonisci neurokininy PL
JP3199300B2 (ja) * 1994-05-09 2001-08-13 三共株式会社 １−メチルカルバペネム誘導体
JP2965922B2 (ja) * 1995-12-21 1999-10-18 三共株式会社 １−メチルカルバペネム誘導体
NZ324447A (en) 1995-12-21 1999-08-30 Sankyo Co 1-methyl-carbapenem substituted by a 4-pyrrolidinylthio group and medicaments
JP2955276B2 (ja) * 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) * 1998-03-19 2010-06-30 富山化学工業株式会社 ５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
KR100686988B1 (ko) 1999-07-06 2007-02-27 메틸진, 인크. β-락타마제의 술폰아미도메틸 포스포네이트 저해제
PL353745A1 (en) 1999-08-10 2003-12-01 British Biotech Pharmaceuticals Limitedbritish Biotech Pharmaceuticals Limited Antibacterial agents
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
PT1340757E (pt) 2000-11-16 2006-12-29 Sankyo Co Derivados 1-metilcarbapenem
JP2002212182A (ja) * 2000-11-16 2002-07-31 Sankyo Co Ltd １−メチルカルバペネム誘導体
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) * 2002-05-15 2004-02-12 Sankyo Co Ltd １−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
EP2298323A3 (en) 2003-07-09 2011-05-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
JP2008502583A (ja) * 2003-10-01 2008-01-31 バイエル・ヘルスケア・アクチェンゲゼルシャフト 抗細菌性アミド大員環
WO2005082050A2 (en) 2004-02-24 2005-09-09 Ssci, Inc. Analysis and screening of solid forms using the atomic pair distribution function
PL1965798T3 (pl) * 2005-12-07 2012-02-29 Basilea Pharmaceutica Ag Użyteczne antybiotyki monobaktamowe
AU2007300531A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
CA2712783C (en) * 2008-01-18 2013-03-19 Timothy A. Blizzard Beta-lactamase inhibitors

Also Published As

Publication number Publication date
HUS000504I2 (hu) 2021-03-29
CY1116243T1 (el) 2017-03-15
AU2009206119A1 (en) 2009-07-23
AU2009206119C1 (en) 2016-05-26
HUS2000024I1 (hu) 2021-03-29
CY2020025I1 (el) 2020-11-25
ES2533826T3 (es) 2015-04-15
MX2010007823A (es) 2010-08-10
DOP2010000218A (es) 2010-08-31
DK2231667T3 (da) 2013-12-16
ES2433744T3 (es) 2013-12-12
EP2231667B1 (en) 2013-09-04
LTC2231667I2 (lt) 2021-07-26
RU2445314C9 (ru) 2013-04-10
HRP20150269T1 (hr) 2015-04-24
BRPI0906871B1 (pt) 2021-09-28
LTPA2020518I1 (lt) 2020-07-27
RU2445314C1 (ru) 2012-03-20
CR11626A (es) 2010-09-13
PT2231667E (pt) 2013-12-13
UA101966C2 (en) 2013-05-27
NL301051I2 (nl) 2020-09-03
CN101918407B (zh) 2014-02-26
US20130274475A1 (en) 2013-10-17
JP5038509B2 (ja) 2012-10-03
CO6331438A2 (es) 2011-10-20
SI2666774T1 (sl) 2015-04-30
BRPI0906871A2 (pt) 2020-07-28
IL206395A (en) 2015-04-30
CY1114900T1 (el) 2016-12-14
NI201000115A (es) 2011-07-08
FR20C1031I1 (el) 2020-02-10
NL301050I2 (nl) 2020-09-03
EP2231667A2 (en) 2010-09-29
SI2231667T1 (sl) 2013-12-31
LUC00165I2 (el) 2021-08-16
HN2010001395A (es) 2012-11-12
MA32025B1 (fr) 2011-01-03
FR20C1030I2 (fr) 2021-08-27
RS53862B1 (en) 2015-08-31
HRP20131123T1 (hr) 2013-12-20
FR20C1030I1 (fr) 2020-02-10
IL206395A0 (en) 2010-12-30
WO2009091856A2 (en) 2009-07-23
FR20C1031I2 (fr) 2022-07-29
CN101918407A (zh) 2010-12-15
EP2666774B1 (en) 2015-01-07
CY2020024I1 (el) 2020-11-25
HK1143809A1 (en) 2011-01-14
PT2666774E (pt) 2015-04-13
JP2011207900A (ja) 2011-10-20
LTC2666774I2 (lt) 2022-01-25
CY2020023I1 (el) 2020-11-25
PL2231667T3 (pl) 2014-01-31
HUS2000023I1 (hu) 2021-03-29
NO2020024I1 (no) 2020-08-10
ECSP10010345A (es) 2010-08-31
CN102827067A (zh) 2012-12-19
US8487093B2 (en) 2013-07-16
DK2666774T3 (en) 2015-03-23
ME02089B (me) 2014-04-30
US20110294777A1 (en) 2011-12-01
AU2009206119B2 (en) 2012-06-07
FR20C1032I2 (fr) 2022-07-29
KR101800610B1 (ko) 2017-11-23
KR20160099117A (ko) 2016-08-19
CN102827067B (zh) 2015-09-23
HK1186180A1 (en) 2014-03-07
JP2011510012A (ja) 2011-03-31
KR101648728B1 (ko) 2016-08-17
JP5422020B2 (ja) 2014-02-19
WO2009091856A3 (en) 2009-12-03
CY2020025I2 (el) 2020-11-25
CA2712783A1 (en) 2009-07-23
FR20C1032I1 (el) 2020-02-10
CA2712783C (en) 2013-03-19
HUS000513I2 (hu) 2021-03-29
PL2666774T3 (pl) 2015-06-30
ECSP10010568A (es) 2010-11-30
JP2012214475A (ja) 2012-11-08
LTPA2020517I1 (lt) 2020-07-27
KR20100130176A (ko) 2010-12-10
EP2666774A1 (en) 2013-11-27
NZ586861A (en) 2011-12-22
ZA201005333B (en) 2011-04-28
RS53052B (en) 2014-04-30
CY2020024I2 (el) 2020-11-25
MY162532A (en) 2017-06-15
LTPA2020516I1 (lt) 2020-07-27
JP5597164B2 (ja) 2014-10-01

Similar Documents

Publication Publication Date Title
CY2020024I1 (el) Αναστολεiς βητα-λακταμασων
CY2017016I2 (el) Αναστολεις πρωτεασωματος
BRPI0907376A2 (pt) Fotobiorretador
DE602009000234D1 (de) msignals
BRPI0918564A2 (pt) inibidores
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0907522A2 (pt) biarlamidas
BRPI0909634A2 (pt) 2-aminoquinolinas
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
DK2240506T3 (da) IAP inhibitorer
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0909637A2 (pt) 2-aminoquinolinas
DE112009000183A5 (de) Sicherheitsvorreiber
DE602009000862D1 (de) Gehwagenbremse
AT507449A3 (de) Dämmstoffbefestiger
DE602009001190D1 (de) Gleichstromumrichtervorrichtung
DK2331548T3 (da) Proteasehæmmere
FI20115213A (fi) Vaarnalenkki
ES1067763Y (es) Dendrometro
DE102008019532B8 (de) Ölvormischbrenner
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita